Apellis Pharmaceuticals Inc
APLS24.113USD
+1.163+5.07%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
3.04BCap. mercado
PérdidaP/E TTM
Más Datos de Apellis Pharmaceuticals Inc Compañía
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.
Información de la empresa
Símbolo de cotizaciónAPLS
Nombre de la empresaApellis Pharmaceuticals Inc
Fecha de salida a bolsaNov 09, 2017
Director ejecutivoDr. Cedric Francois, M.D., Ph.D.
Número de empleados705
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 09
Dirección100 Fifth Avenue
CiudadWALTHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02451
Teléfono16179775700
Sitio Webhttps://apellis.com/
Símbolo de cotizaciónAPLS
Fecha de salida a bolsaNov 09, 2017
Director ejecutivoDr. Cedric Francois, M.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
112.58K
-4.25%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
16.48K
--
Ms. Keli Walbert
Ms. Keli Walbert
Independent Director
Independent Director
9.09K
--
Ms. Stephanie Monaghan O'Brien, J.D.
Ms. Stephanie Monaghan O'Brien, J.D.
Independent Director
Independent Director
955.00
-86.25%
Mr. Niel Carnahan
Mr. Niel Carnahan
Investor Contact
Investor Contact
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
112.58K
-4.25%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Por negocioUSD
Nombre
Ganancia
Proporción
SYFOVRE
130.17M
78.04%
EMPAVELI
19.73M
11.83%
Licensing and other revenue
16.90M
10.13%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
SYFOVRE
130.17M
78.04%
EMPAVELI
19.73M
11.83%
Licensing and other revenue
16.90M
10.13%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Morningside Venture Investments, Ltd.
10.14%
Wellington Management Company, LLP
9.74%
Avoro Capital Advisors LLC
9.68%
EcoR1 Capital, LLC
9.42%
The Vanguard Group, Inc.
8.01%
Other
53.01%
Accionistas
Accionistas
Proporción
Morningside Venture Investments, Ltd.
10.14%
Wellington Management Company, LLP
9.74%
Avoro Capital Advisors LLC
9.68%
EcoR1 Capital, LLC
9.42%
The Vanguard Group, Inc.
8.01%
Other
53.01%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
47.44%
Investment Advisor
24.12%
Hedge Fund
15.28%
Research Firm
11.85%
Corporation
10.19%
Individual Investor
3.82%
Bank and Trust
1.65%
Pension Fund
1.30%
Private Equity
1.14%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
707
147.98M
117.74%
-16.68M
2025Q1
739
147.63M
117.48%
-17.38M
2024Q4
726
148.40M
118.39%
-6.44M
2024Q3
713
138.62M
113.64%
-12.05M
2024Q2
701
135.38M
111.32%
-9.63M
2024Q1
699
132.74M
109.77%
-12.51M
2023Q4
669
131.80M
110.59%
-13.78M
2023Q3
642
131.99M
111.79%
-7.62M
2023Q2
631
124.43M
106.07%
-15.68M
2023Q1
592
129.73M
111.79%
-2.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Morningside Venture Investments, Ltd.
12.81M
10.19%
--
--
Mar 31, 2025
Wellington Management Company, LLP
12.30M
9.79%
+502.40K
+4.26%
Mar 31, 2025
Avoro Capital Advisors LLC
12.22M
9.72%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
11.90M
9.46%
+4.96K
+0.04%
Mar 31, 2025
The Vanguard Group, Inc.
10.11M
8.05%
+84.33K
+0.84%
Mar 31, 2025
Morgan Stanley & Co. LLC
8.10M
6.44%
+40.85K
+0.51%
Mar 31, 2025
Deep Track Capital LP
7.00M
5.57%
+2.00M
+40.00%
May 09, 2025
BlackRock Institutional Trust Company, N.A.
5.43M
4.32%
-8.41K
-0.15%
Mar 31, 2025
AQR Capital Management, LLC
4.08M
3.24%
+2.22M
+119.64%
Mar 31, 2025
State Street Global Advisors (US)
3.94M
3.14%
-583.75K
-12.90%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
1.73%
ALPS Medical Breakthroughs ETF
1.47%
Global X Guru Index ETF
1.21%
SPDR S&P Biotech ETF
0.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
Invesco Nasdaq Biotechnology ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Biotechnology ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
First Trust Small Cap Growth AlphaDEX Fund
0.09%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción1.73%
ALPS Medical Breakthroughs ETF
Proporción1.47%
Global X Guru Index ETF
Proporción1.21%
SPDR S&P Biotech ETF
Proporción0.63%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.36%
Invesco Nasdaq Biotechnology ETF
Proporción0.24%
ProShares Ultra Nasdaq Biotechnology
Proporción0.24%
iShares Biotechnology ETF
Proporción0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proporción0.09%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.09%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
